BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

247 related articles for article (PubMed ID: 16381682)

  • 1. Properties of the Feynman-alpha method applied to accelerator-driven subcritical systems.
    Taczanowski S; Domanska G; Kopec M; Janczyszyn J
    Radiat Prot Dosimetry; 2005; 115(1-4):58-62. PubMed ID: 16381682
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Design of a new IRSN thermal neutron field facility using Monte-Carlo simulations.
    Lacoste V
    Radiat Prot Dosimetry; 2007; 126(1-4):58-63. PubMed ID: 17578877
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Measurement and analysis of induced activities in concrete irradiated using high-energy neutrons at KENS Neutron Spallation Source Facility.
    Oishi K; Nakao N; Kosako K; Yamakawa H; Nakashima H; Kawai M; Yashima H; Sanami T; Numajiri M; Shibata T; Hirayama H; Nakamura T
    Radiat Prot Dosimetry; 2005; 115(1-4):623-9. PubMed ID: 16381795
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The TRADE experiment: shielding calculations for the building hosting the subcritical system.
    Burn KW; Carta M; Casalini L; Kadi Y; Monti S; Nava E; Palomba M; Petrovich C; Picardi L; Rubbia C; Troiani F
    Radiat Prot Dosimetry; 2005; 115(1-4):187-94. PubMed ID: 16381710
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Shielding analysis at the upper section of the accelerator-driven system.
    Sasa T; Yang JA; Oigawa H
    Radiat Prot Dosimetry; 2005; 116(1-4 Pt 2):256-8. PubMed ID: 16604639
    [TBL] [Abstract][Full Text] [Related]  

  • 6. MCNPX vs. DORT for SNS shielding design studies.
    Popova II
    Radiat Prot Dosimetry; 2005; 115(1-4):559-63. PubMed ID: 16381785
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Gelina neutron target optimisation.
    Flaska M; Plompen AJ; Mondelaers W; Lathouwers D; van der Hagen TH; van Dam H
    Radiat Prot Dosimetry; 2005; 115(1-4):408-11. PubMed ID: 16381756
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Analysis of neutron and gamma-ray streaming along the maze of NRCAM thallium production target room.
    Raisali G; Hajiloo N; Hamidi S; Aslani G
    Appl Radiat Isot; 2006 Aug; 64(8):940-7. PubMed ID: 16713275
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Conceptual design of spectrum changeable neutron calibration fields in JAERI/FRS.
    Saegusa J; Tanimura Y; Yoshizawa M; Yoshida M
    Radiat Prot Dosimetry; 2004; 110(1-4):91-5. PubMed ID: 15353628
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dosimetric considerations on TEPC fluka-simulation and measurements.
    Rollet S; Beck P; Ferrari A; Pelliccioni M; Autischer M
    Radiat Prot Dosimetry; 2004; 110(1-4):833-7. PubMed ID: 15353755
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Calculations of anisotropy factors for radionuclide neutron sources due to scattering from source encapsulation and support structures.
    Tsujimura N; Yoshida T; Momose T
    Radiat Prot Dosimetry; 2007; 126(1-4):168-73. PubMed ID: 17575299
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Measurement and calculation of the emission anisotropy of an X1 252Cf neutron source.
    Hawkes NP; Freedman R; Tagziria H; Thomas DJ
    Radiat Prot Dosimetry; 2007; 126(1-4):78-82. PubMed ID: 17496296
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Study of the neutron beam line shield design for JSNS.
    Kawai M; Saito K; Sanami T; Nakao N; Maekawa F
    Radiat Prot Dosimetry; 2005; 115(1-4):580-6. PubMed ID: 16381789
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Neutron shielding calculations in a proton therapy facility based on Monte Carlo simulations and analytical models: criterion for selecting the method of choice.
    Titt U; Newhauser WD
    Radiat Prot Dosimetry; 2005; 115(1-4):144-8. PubMed ID: 16381702
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Radioprotection calculations for MEGAPIE.
    Zanini L
    Radiat Prot Dosimetry; 2005; 116(1-4 Pt 2):95-8. PubMed ID: 16604605
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Response of neutron detectors to high-energy mixed radiation fields.
    Mayer S; Forkel-Wirth D; Fuerstner M; Menzel HG; Mueller MJ; Perrin D; Theis C; Vincke H
    Radiat Prot Dosimetry; 2007; 125(1-4):289-92. PubMed ID: 17337743
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluation of the photoneutron field produced in a medical linear accelerator.
    Kim HS; Park YH; Koo BC; Kwon JW; Lee JS; Choi HS
    Radiat Prot Dosimetry; 2007; 123(3):323-8. PubMed ID: 17077093
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Multileaf shielding design against neutrons produced by medical linear accelerators.
    Rebello WF; Silva AX; Facure A
    Radiat Prot Dosimetry; 2008; 128(2):227-33. PubMed ID: 17569690
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Results of field trials using the NPL simulated reactor neutron field facility.
    Taylor GC; Thomas DJ; Bennett A
    Radiat Prot Dosimetry; 2007; 126(1-4):89-92. PubMed ID: 17848380
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Propagation characteristics of neutrons leaking from the accelerator facilities.
    Kitaichi M; Sawamura S; Wakisaka M; Kaneko JH; Ochiai K; Nishitani T; Sawamura T
    Radiat Prot Dosimetry; 2004; 110(1-4):731-8. PubMed ID: 15353739
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.